Get the Stockscreener App
1.26
0.00%
0.00
Vivani Medical Inc stock is traded at $1.26, with a volume of 27,791.
It is up +0.00% in the last 24 hours and up +6.78% over the past month.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
See More
Previous Close:
$1.26
Open:
$1.24
24h Volume:
27,791
Relative Volume:
0.39
Market Cap:
$69.62M
Revenue:
-
Net Income/Loss:
$-25.65M
P/E Ratio:
-3.2308
EPS:
-0.39
Net Cash Flow:
$-24.59M
1W Performance:
-3.08%
1M Performance:
+6.78%
6M Performance:
-29.21%
1Y Performance:
+17.76%
1-Day Range:
$1.22
$1.265
1-Week Range:
$1.22
$1.35
52-Week Range:
$0.84
$7.80
Vivani Medical Inc Stock (VANI) Company Profile
Name
Vivani Medical Inc
Sector
Industry
Phone
818-833-5000
Address
1350 S. LOOP ROAD, ALAMEDA
Vivani Medical Inc Stock (VANI) Latest News
3 US Penny Stocks To Monitor In October 2024 - Simply Wall St
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024 - Business Wire
Vivani Medical's Market Cap Up US$6.6m Following Year Of Insider Stock Buying - Simply Wall St
Vivani Medical (NASDAQ:VANI) Shares Up 0.9%Here's Why - MarketBeat
Vivani Medical's chief business officer buys shares worth $2,835 - Investing.com India
Vivani Medical's chief business officer buys shares worth $2,835 By Investing.com - Investing.com Australia
Precision Optics (OTCMKTS:PEYE) & Vivani Medical (NASDAQ:VANI) Head-To-Head Analysis - Defense World
Vivani Medical (NASDAQ:VANI) Stock Quotes, Forecast and News Summary - Benzinga
Vivani Medical obtains Australian approval to begin GLP-1 implant trial - Yahoo Finance
Vivani Medical's implant trial gets Australian regulatory nod - Investing.com Australia
Vivani Medical's implant trial gets Australian regulatory nod By Investing.com - Investing.com Canada
Vivani Medical to Test Implant in Obese and Overweight Patients - Yahoo Finance
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia - Business Wire
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia - Yahoo Finance
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Yahoo! Voices
Ventyx stock climbs 8% on $27M Sanofi investment - MSN
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson's candidate for $27M - Fierce Biotech
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I - Pharmaceutical Technology
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024 - Business Wire
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment - Marketscreener.com
Commonwealth Equity Services LLC Has $416,000 Stock Position in Vivani Medical, Inc. (NASDAQ:VANI) - Defense World
Viva Leisure Continues Share Buy-Back Initiative - TipRanks
First Eagle Investment Management LLC Purchases New Holdings in Silvaco Group, Inc. (NASDAQ:SVCO) - MarketBeat
Form 425 Revelyst, Inc. Filed by: Vista Outdoor Inc. - StreetInsider.com
Vista Outdoor Board of Directors Sends Letter to Stockholders Highlighting Reasons to Vote FOR Value Maximizing CSG Transaction - Yahoo Finance
Viva Leisure Continues Share Buy-Back Effort - TipRanks
Vista Outdoor considering sale of Revelyst, urges transaction with CSG - MSN
Vista Outdoor considering sale of Revelyst, urges transaction with CSG (VSTO) - Seeking Alpha
Vivani Medical (NASDAQ:VANI) Shares Down 2.3% - MarketBeat
Vivani Medical (NASDAQ:VANI) Trading Down 2.3% - Defense World
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity - MSN
Stock Performance Spotlight: Vivani Medical Inc (VANI) Ends the Day at 1.21, Down by -1.63 - The Dwinnex
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant - Morningstar
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying - MSN
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Items Tagged with 'Vivani Medical Inc.' - BioWorld Online
Implant still can’t; Vivani bonny vs. Intarcia with exenatide? - BioWorld Online
We Think Vivani Medical (NASDAQ:VANI) Needs To Drive Business Growth Carefully - Simply Wall St
Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation - Yahoo Finance
Vivani Medical: Q2 Earnings Snapshot - San Antonio Express-News
VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024 - InvestorPlace
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results - StockTitan
Vivani Medical Inc expected to post a loss of 12 cents a shareEarnings Preview - XM
ENDRA Life Sciences (NASDAQ:NDRA) and Vivani Medical (NASDAQ:VANI) Critical Contrast - Defense World
Vivani Medical's chief business officer buys shares worth $11,120 - Investing.com
Vivani Medical's chief business officer buys $1.92k in company stock - Investing.com Canada
Vivani Medical, Inc. (NASDAQ:VANI) Sees Large Drop in Short Interest - American Banking and Market News
Vivani Medical, Inc. (NASDAQ:VANI) Sees Significant Decline in Short Interest - Defense World
TransMedics Group (NASDAQ:TMDX) & Vivani Medical (NASDAQ:VANI) Head-To-Head Survey - Defense World
Vivani Medical Inc Stock (VANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):